Immunity Pharma Ltd.
IPL develops drugs that activate self-healing processes in neurologic diseases. Our lead drug IPL344 has a strong case for stabilizing ALS.
We develop innovative drugs that stimulate therapeutic cell-signalling processes for the treatment of neuro-degenerative diseases, with an initial focus on ALS (Lou Gehrig's disease) - which has no cure, and massive market potential. Our drug bypasses cracks in the signalling processes induced by the disease conditions and has potential to succeed when many other drugs failed. We are now approaching Phase I-II clinical trial with ALS patients